RABL3

Across TCGA pan-cancer cohorts, RABL3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RABL3 data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RABL3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RABL3 expression acts as an unfavorable survival marker.

LUAD and READ are the cancer types where RABL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.098	0.768	<.001	15	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RABL3–LUAD (DFS)

Open the LUAD breakdown →